The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions

Golu, Ioana; Vlad, Mihaela; Dema, Alis; Moleriu, Lavinia Cristina; Tudor, Anca; Iacob, Mihaela; Popa, Oana; Cornianu, Mărioara

doi:10.4103/0377-4929.208378

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Several studies were conducted in which CD56 immunohistochemistry has differentiated PTC from benign thyroid lesions like FA, NH, and HT, the differences being statistically significant (p= < 0.0001). 22 Similar results were also obtained in our study (p=< 0.0001). No statistical significance was observed by comparing CD56 expression of NH and HT with FA.…”

Section: Discussionsupporting

confidence: 91%

Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid

Shameem¹,

Fatima²,

Myla³

2020

IJPO

View full text Add to dashboard Cite

Background: Thyroid cancer is one of the most common malignant neoplasm worldwide. Among Indians, thyroid cancer constitutes 3.96% of total cancers. Papillary thyroid carcinoma (PTC) is a malignant epithelial tumor with distinctive nuclear features. PTC represents, about 85% of all malignant thyroid neoplasm. Though histopathological diagnosis is the gold standard for PTC diagnosis, pathologists usually face difficulty due to morphologic overlap between follicular neoplasms and PTC, especially the follicular variant of PTC. CD56 is a neuroendocrine marker and an antigen important for the follicular epithelium differentiation. Recent studies have reported low or absent expression of CD56 in PTC and its presence in normal thyroid tissue, benign thyroid lesions, and most follicular non-PTC tumors. Aims: This study aimed to assess the diagnostic utility of immunohistochemical marker, CD56 in distinguishing PTC from benign thyroid lesions and follicular neoplasms. Materials and Methods: This was a prospective and retrospective case control study conducted at department of Pathology of our institute. All 125 thyroidectomy specimens received during a study period from January 2017 to December 2019 were studied and any already established recurrent case of PTC was excluded. After routine histopathological examination, the expression of CD56 was studied and statistically analyzed. Results: The difference between expression of CD56 antibody in differentiating PTC from other thyroid lesions was found to be statistically significant (p=<0.001). The sensitivity of CD56 was 94.6%, and its specificity was 97.7%. Conclusion: Thus, CD56 was found to be a valuable and sensitive biomarker even when used individually.

show abstract

Section: Discussionsupporting

confidence: 91%

Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid

Shameem¹,

Fatima²,

Myla³

2020

IJPO

View full text Add to dashboard Cite

show abstract

“…HBME-1 displayed high sensitivity and high specificity in detecting PTC in many cases [ 34 ]. Additional reports suggest that mixed panels of immunostaining markers would provide more accurate diagnoses [ 12 - 16 , 20 , 22 , 25 , 26 , 33 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

The Usefulness of Immunocytochemistry of CD56 in Determining Malignancy from Indeterminate Thyroid Fine-Needle Aspiration Cytology

Cha

Pyo

Hong³

2018

J Pathol Transl Med

View full text Add to dashboard Cite

BackgroundFine-needle aspiration cytology serves as a safe, economical tool in evaluating thyroid nodules. However, about 30% of the samples are categorized as indeterminate. Hence, many immunocytochemistry markers have been studied, but there has not been a single outstanding marker. We studied the efficacy of CD56 with human bone marrow endothelial cell marker-1 (HBME-1) in diagnosis in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category III.MethodsWe reviewed ThinPrep liquid-based cytology (LBC) samples with Papanicolaou stain from July 1 to December 31, 2016 (2,195 cases) and selected TBSRTC category III cases (n = 363). Twenty-six cases were histologically confirmed as benign (six cases, 23%) or malignant (20 cases, 77%); we stained 26 LBC slides with HBME-1 and CD56 through the cell transfer method. For evaluation of reactivity of immunocytochemistry, we chose atypical follicular cell clusters.ResultsCD56 was not reactive in 18 of 20 cases (90%) of malignant nodules and showed cytoplasmic positivity in five of six cases (83%) of benign nodules. CD56 showed high sensitivity (90.0%) and relatively low specificity (83.3%) in detecting malignancy (p = .004). HBME-1 was reactive in 17 of 20 cases (85%) of malignant nodules and was not reactive in five of six cases (83%) of benign nodules. HBME-1 showed slightly lower sensitivity (85.0%) than CD56. The specificity in detecting malignancy by HBME-1 was similar to that of CD56 (83.3%, p = .008). CD56 and HBME-1 tests combined showed lower sensitivity (75.0% vs 90%) and higher specificity (93.8% vs 83.3%) in detecting malignancy compared to using CD56 alone.ConclusionsUsing CD56 alone showed relatively low specificity despite high sensitivity for detecting malignancy. Combining CD56 with HBME-1 could increase the specificity. Thus, we suggest that CD56 could be a useful preoperative marker for differential diagnosis of TBSRTC category III samples.

show abstract

“…Считается, что CD56 участвует в регуляции клеточной подвижности, гомофильной связи между нейронами, стимуляции роста нервов, а его экспрессия может влиять на миграционную способность опухолевых клеток. Согласно результатам недавних исследований, сниженная экспрессия данного белка способствует метастатическому распространению опухолевых клеток в регионарные лим фатические узлы за счет повышенной экспрессии лимфангиогенных факторов VEGF-C и VEGF-D [32]. Помимо этого, сниженная экспрессия CD56 коррелирует с метастатическим потенциалом и неблагоприятным прогнозом в отношении выживаемости, что может иметь диагностическую ценность при дифференциальной диагностике ПРЩЖ и ее доброкачественных поражений, при которых экспрессия этого белка нормальная или высокая [29,33].…”

Section: белковые маркеры ассоциированные с раком щитовидной железыunclassified

Modern concepts of the molecular pathogenesis of thyroid cancer

et al. 2021

View full text Add to dashboard Cite

Thyroid cancer remains the most common malignancy of the endocrine system worldwide. The indicators of its morbidity and mortality rates have been increasing rapidly over the last decades. Most cases of differentiated thyroid cancer (follicular and papillary histotypes) are clinically manifested by nodular goiter frequently combined with uncertain results of cytological diagnosis (categories III and IV according to the Bethesda (Bethesda System for Reporting Thyroid Cytopathology) classification). All of that makes it difficult to choose a proper tactic for patient treatment. It is known that the development, progression, invasion, and metastasis of cancer cells are regulated by a variety of molecular mechanisms. This review describes several molecular aspects of thyroid nodules oncogenesis, as well as its most promising diagnostic tumor markers. Following molecular pathways are described in particular: gene mutations, protein tumor markers, and epigenetic effects of micro-RNA, histones, as well as DNA methylation. The study of the pathogenesis of this disease has a prognostic value and contributes to the search for effective therapeutic and diagnostic methods and their improvement. That is why we also reviewed modern test panels aimed at preoperative differential diagnosis of thyroid nodules. Summarizing the results of world research on this topic allows us not only to expand the understanding of the fundamental processes of oncogenesis, but also to outline promising areas for future experimental research projects. All of that together will contribute to developing new prognostic, diagnostic and therapeutic technologies, and as a result, will improve the quality of medical care for patients with thyroid cancer.

show abstract

The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions

Abstract: CD56 has been proved to be a useful marker in the diagnosis of PTC, including FV-PTC. Its absence can help differentiate FV-PTC from other thyroid nodules with follicular patterns.

Cited by 6 publications

References 0 publications

Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid

Diagnostic utility of CD56 in differentiating papillary thyroid carcinoma from other lesions of thyroid

The Usefulness of Immunocytochemistry of CD56 in Determining Malignancy from Indeterminate Thyroid Fine-Needle Aspiration Cytology

Modern concepts of the molecular pathogenesis of thyroid cancer

Contact Info

Product

Resources

About